2022 | Ifm_05-may

The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.

Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen. IFM_05-May 2022

One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations The study demonstrated a clear overall survival benefit

Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. A significant number of patients (roughly 27%) had

Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team.

A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.

Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI